ArticleVox sanguinis2026
Effective resolution of daratumumab-induced false-positive antibody screening with commercial reagents.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic biologics interference in serological and pre-transfusion testing.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
objectivesDaratumumab (DARA), an anti-CD38 monoclonal antibody used in the treatment of multiple myeloma, frequently causes false-positive panreactivity in antibody screening tests. The conventional approach to resolve this interference involves treating reagent red blood cells (RBCs) with 0.2 M dithiothreitol (DTT). However, this method is labour-intensive, may fail to detect clinically significant antibodies and can yield inconsistent results. We aimed to assess the effectiveness of a commercial reagent containing anti-CD38 Fab fragments as an alternative for mitigating DARA-related interference. MATERIALS AND
methodsWe retrospectively analysed 22 blood samples from 17 patients. Antibody screening was performed using both DTT-treated and DaraEx-treated reagent RBCs. Clinical and laboratory data were reviewed. Additionally, patient samples were spiked with antibodies to evaluate antibody detection.
resultsAll samples showed false-positive panreactivity after DARA treatment. Nineteen samples were negative using both DTT- and DaraEx-treated cells. Three samples remained reactive with DTT-treated cells but turned negative with DaraEx. These cases were associated with lower serum albumin, impaired renal function and elevated monoclonal protein levels. DaraEx-treated cells retained reactivity with anti-E and anti-D antibodies.
conclusionDaraEx consistently and completely removed DARA-related interference, including in cases where DTT was ineffective. It represents a safe and efficient alternative to DTT for pre-transfusion antibody screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.